Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.


TSX:SVA - Post by User

Comment by donkeyfeatherson Mar 21, 2021 1:54pm
279 Views
Post# 32847109

RE:RE:RE:Today's Trading

RE:RE:RE:Today's Trading

So Red…no comments since “As for those still going off about the BD you have to realize these don't just come out of thin air.  This BD was well underway long before we broke out of the 60c-70 range.  It’s all part of the process and it’s not over yet IMO.”

 

I have to say your prolonged silence even after a shareholder presentation, is quite the flag wave.  Those of us who have been on this story for a while (and for whom a few rodeos have passed) could speculate on the timing of when the SVA board talks with institutional investors began in earnest, but far fewer would have the road (selphie-type) apples to come out in a public forum and make the case you did. The case that despite the run-up post Witkowski presentation, new share valuation had already been established “as range” between the institutions and the board, despite what the retailers hearing the news thought the price should be.

 

Simply put, whether you intended to or not, you raised suspicions around who is privy to material information prior to a general announcement.  Watching the re-broadcast of Fridays “show” I took this hypothesis in when listening to how Phillip answered the questions in part 2 of the presentation.

 

All I can say is, Phillip “ducked and weaved” his way even more when it came to “how’s the money going to be used” than the questions around “where’s the science going next.”  If there were talks in play around institutional investment in SVA prior to the Witkowski presentation as I’m sure we can all agree there were, then the board also knew that the speculative run that would inevitably follow, would be in jeopardy if anyone onboarding at $2+ knew a BD was in the works.

 

This is the part where folk like Elgin and Rixpix and myself ask WTF?  Even if you are long, we are not privy to the full prospectus of what’s happening on the financial front.  And the subsequent investor’s livestream does nothing to add any colour.  It’s at this point that you can’t accuse retail shareholders of being naive, but you can ask - at an AGM - if the claim that Phillip repeats (his love and respect for legacy shareholders) has anything to do with the timing and detail availability in information shared FORMALLY.  Because if it is, then all those that bought in at over $1.70 were just mass casualties and nothing more (too bad).  I’m glad I wasn’t one of those with a target on my back as my shares are already “free”, and I do believe we are at a new valuation because of the de-risking efforts up till now.  

 

But to say that Phillip the scientist is Phillip the investor’s financier, is a bridge way too far.  Maybe like opining BD’s are well underway, when only those constructing “the way” are aware of what’s happening “behind the scenes” which the retail investor can’t see.  Again, the SVA board is playing games that could put all of our investments in a tough place if they pretend to be forthcoming, when really what they are doing is trying to distract and deflect.  April is not far off…time to start dusting off some tough questions while having the constitution to demand answers IMO.

DF

<< Previous
Bullboard Posts
Next >>